According to Future Market Insights, the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market demand is expected to grow at a 6.9% CAGR from 2023 to 2033. The global market for Chimeric antigen receptor (CAR) T-Cell Therapy is expected to reach US$ 6.82 billion by 2033. One of the primary benefits of CAR T-Cell Therapy is its high efficacy rates. CAR T-Cell Therapy has showed up to 90% response rates in clinical trials in some types of leukaemia and lymphoma. This represents a significant advancement above conventional cancer treatments, which normally have response rates of 20-30%.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16808
The prospect of long-term remissions is another advantage of CAR T-Cell Therapy. In certain cases, CAR T-Cell Therapy has resulted in total remission, which implies that there is no evidence of cancer in the body. This is especially hopeful for people who have relapsed or refractory cancer and have exhausted all other treatment options.
As additional clinical trials are completed and drugs are licenced, the market for CAR T-Cell Therapy is expected to grow in the future years. In addition to the two currently approved drugs, several more CAR T-Cell Therapy treatments for different cancers are in late-stage clinical trials. Advances in gene editing technology are also expected to enhance the industry, enabling for the development of more effective CAR T-cell therapies with fewer side effects.
Key Takeaways from the Market Study
- The Chimeric antigen receptor (CAR) T-Cell Therapy market is estimated to expand at a 6.9% CAGR from 2023 to 2033.
- Yescarta is predicted to have 45% of the market share for Chimeric antigen receptor (CAR) T-Cell Therapy in 2023.
- In 2023, North America is estimated to hold 45% of the market for Chimeric antigen receptor (CAR) T-Cell Therapy.
- In 2023, Europe's Chimeric Antigen Receptor (CAR) T-Cell Therapy market is estimated to account for 39% of the total.
“The increasing incidence of cancer, rising demand for personalized medicine, and advancements in CAR T-Cell Therapy are some of the major factors driving the growth of the market,” states an FMI analyst.
Last few days to get reports at discounted prices, offer expires soon!
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16808
Competitive Landscape
Key players in the Chimeric antigen receptor (CAR) T-Cell Therapy market are Abbott Laboratories, Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Fresenius SE & Co. KGaA, Johnson & Johnson, Medtronic PLC, Novartis AG, Endo International PLC and Pfizer Inc.
- BD has contributed to CAR T-Cell Therapy is through its flow cytometry technology, which is used to monitor the manufacturing and quality control of CAR T-cell therapies. Flow cytometry is a technique that allows researchers and clinicians to analyze and sort individual cells based on their physical and chemical characteristics. BD offers a range of flow cytometry instruments and reagents that are used to monitor the T-cells used in CAR T-Cell Therapy, as well as the cancer cells targeted by these therapies.
- Boston Scientific has contributed to CAR T-Cell Therapy through its interventional oncology products. These products are designed to treat cancer through minimally invasive procedures, such as tumor ablation or embolization. While these procedures are not directly related to CAR T-Cell Therapy, they can be used to manage complications that may arise during or after CAR T-cell treatment, such as bleeding or swelling in the liver.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global chimeric antigen receptor (CAR) T-Cell Therapy market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
For Report Customization, connect with us@ https://www.futuremarketinsights.com/customization-available/rep-gb-16808
Key Segments Profiled in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Survey
By Type:
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- Others
By Application:
- Leukemia
- Lymphoma
- Multiple Myeloma
- Autoimmune Disorders
- Other Application
By End User:
- Hospitals
- Cancer Care Treatment Centers
